62772-70-7

Usage

Uses

Used in Pharmaceutical Development:
ETHYL 2-METHYL-IMIDAZO[1,2-A]PYRIMIDINE 3-CARBOXYLATE is used as a key intermediate in the synthesis of pharmaceutical drugs. Its unique structure and functional groups contribute to the development of new therapeutic agents with potential applications in treating various diseases and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, ETHYL 2-METHYL-IMIDAZO[1,2-A]PYRIMIDINE 3-CARBOXYLATE serves as a versatile building block for the creation of more complex organic molecules. Its reactivity and functional groups allow for a wide range of chemical reactions, facilitating the synthesis of novel compounds with diverse applications.
Used in Medicinal Chemistry Research:
ETHYL 2-METHYL-IMIDAZO[1,2-A]PYRIMIDINE 3-CARBOXYLATE is utilized in medicinal chemistry research to explore its potential as a bioactive molecule. Researchers investigate its interactions with biological targets, such as enzymes, receptors, or other proteins, to understand its pharmacological effects and optimize its properties for therapeutic use.
Used in Drug Design and Optimization:
In the process of drug design and optimization, ETHYL 2-METHYL-IMIDAZO[1,2-A]PYRIMIDINE 3-CARBOXYLATE is employed as a starting point or a structural component in the development of new drug candidates. Its unique features can be modified or combined with other chemical entities to enhance the potency, selectivity, and pharmacokinetic properties of the resulting compounds.
Used in Chemical Libraries:
ETHYL 2-METHYL-IMIDAZO[1,2-A]PYRIMIDINE 3-CARBOXYLATE is incorporated into chemical libraries for high-throughput screening. These libraries contain a vast array of diverse compounds that are tested against various biological targets to identify potential lead compounds for further development into drugs.
Used in Chemical Education and Training:
In academic and research institutions, ETHYL 2-METHYL-IMIDAZO[1,2-A]PYRIMIDINE 3-CARBOXYLATE can be used as a teaching aid in chemical education and training programs. It provides students and researchers with hands-on experience in handling and synthesizing complex organic molecules, fostering a deeper understanding of chemical reactions and drug development processes.

InChI:InChI=1/C10H11N3O2/c1-3-15-9(14)8-7(2)12-10-11-5-4-6-13(8)10/h4-6H,3H2,1-2H3

Upstream product

• 141-97-9 ethyl acetoacetate 
• 109-12-6 2-aminopyrimidine 
• 84911-18-2 ethyl 2-bromoacetoacetate 
• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 

Downstream Products

• 90830-11-8 2-methyl-imidazo[1,2-a]pyrimidine-3-carboxylic acid 

Relevant academic research and scientific papers

Research on heterocyclic compounds - Part XXXIX. 2-Methylimidazo[1,2-a]pyrimidine-3-carboxylic derivatives: Synthesis and antiinflammatory activity

The synthesis of a group of 2-methylimidazo[1,2-a]pyrimidine-3-carboxylic esters, acids and amides is described. The structures of new compounds are supported by 1H and 13C NMR spectra. These compounds were tested in vivo for their antiinflammatory analgesic and ulcerogenic activity. Eight new compounds out of fifteen showed remarkable dose-dependent antiinflammatory action in die carrageenan rat paw edema (1/2-1/3 x indomethacin) but weak analgesic activity in the acetic acid writhing test together with negligible ulcerogenic action. The new compounds were found to be lacking in inhibitory activity on cyclooxygenase in vitro.

Structural modification of zolpidem led to potent antimicrobial activity in imidazo[1,2-: A] pyridine/pyrimidine-1,2,3-triazoles

Ambien (zolpidem), an imidazo[1,2-a]pyridine derivative, is a commercial drug to treat insomnia which also possesses antitubercular activity against Mycobacterium tuberculosis H37Rv. In this paper, we describe the synthesis of three diverse lead series of imidazo[1,2-a]pyridine/pyrimidine-1,2,3-triazoles (IPTs) which are designed by specific structural modifications of zolpidem. Most of the IPTs exhibited remarkable in vitro antitubercular activity with an MIC of 1.56 μg mL-1, which is two-fold higher than the MIC of zolpidem. Further, the synthesized IPTs displayed moderate inhibitory activity against several bacterial and fungal strains as well, and also showed an acceptable safety profile as verified through in vitro cytotoxicity assessment against Vero cells. In addition, the potent IPTs exhibited promising binding interactions within the active site of the InhA enzyme. An interesting correlation between the in vitro inhibitory activity and the binding mode was observed: most of the potent molecules (MIC = 1.56 μg mL-1) interact through a H-bond with the Tyr 158 residue of the target enzyme. These efforts toward the structural modification of zolpidem could be helpful for further optimization of the IPT core to develop new anti-TB drugs.

NBS mediated protocol for the synthesis of N-bridged fused heterocycles in water

A facile and environmental friendly protocol for the synthesis of N-bridged fused bicyclic compounds such as imidazo[1,2-a]pyridines, imidazo[1,2-a]pyrimidines, and imidazo[2,1-b]thiazole, from commercially available starting materials has been developed.

CBr4 Mediated Oxidative C-N Bond Formation: Applied in the Synthesis of Imidazo[1,2-α]pyridines and Imidazo[1,2-α]pyrimidines

The carbon tetrabromide mediated oxidative carbon-nitrogen bond formation of 2-aminopyridines or 2-aminopyrimidines with β-keto esters or 1,3-diones, leading to a variety of complex imidazo[1,2-α]pyridines or imidazo[1,2-α]pyrimidines, is reported. The re